Agios Pharmaceuticals Receives 'Hold' Rating from Analysts

Analysts maintain a neutral outlook on the biopharmaceutical company's stock performance.

Mar. 31, 2026 at 8:25am

Got story updates? Submit your updates here. ›

A highly detailed, cinematic close-up image of heavy, industrial banking and financial equipment, conveying the complex institutional forces and infrastructure underlying the biopharmaceutical sector.An extreme close-up of the complex financial and technological machinery powering the biopharmaceutical industry, where analyst ratings and market expectations shape the fortunes of innovative drug developers.Cambridge Today

Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) have received a consensus 'Hold' rating from the 11 analysts currently covering the company, according to Marketbeat.com. One analyst has a 'Sell' rating, four have 'Hold' ratings, and six have 'Buy' ratings, with an average 12-month price target of $40.67.

Why it matters

Agios Pharmaceuticals is a prominent biopharmaceutical company focused on developing cancer and rare disease treatments. The analyst ratings and price targets provide insight into Wall Street's current sentiment and expectations for the company's stock performance and future prospects.

The details

The analyst ratings and price targets for Agios Pharmaceuticals reflect a mixed outlook. While a majority of analysts are bullish on the stock, with 'Buy' ratings and an average price target above the current trading price, there is also a sizable contingent of analysts maintaining a neutral 'Hold' stance. This suggests uncertainty around the company's ability to consistently execute on its drug development pipeline and commercialization efforts.

  • Analyst ratings and price targets were reported on March 31, 2026.

The players

Agios Pharmaceuticals, Inc.

A biopharmaceutical company focused on developing cancer and rare disease treatments, headquartered in Cambridge, Massachusetts.

Got photos? Submit your photos here. ›

What’s next

Investors will be closely watching Agios Pharmaceuticals' upcoming earnings reports and pipeline updates to gauge whether the company can deliver on its growth potential and change the minds of analysts currently maintaining a neutral stance.

The takeaway

The mixed analyst ratings for Agios Pharmaceuticals reflect the challenges and uncertainties facing the biopharmaceutical industry, where drug development timelines and commercial success can be difficult to predict. The company's ability to advance its pipeline and execute on its strategy will be key to swaying a more bullish consensus from Wall Street.